Abstract Listings 2024

Purpose

The study aimed to assess the effectiveness and safety of intralesional bleomycin for the treatment of xanthelasma palpebrarum (XP) in a Saudi cohort. A similar study has been conducted exclusively in a Chinese cohort, and this research seeks to provide valuable insights into the applicability and generalizability of this treatment modality on different ethnic group.

Methods

A prospective clinical study was conducted with the approval of the Ethical Committee of Dhahran Eye Specialist Hospital. From May 2023 to June 2024, intralesional bleomycin (7.5 units/mL) was administered to patients with (XP). Informed consent was obtained from all participants. Each patient received two sessions of intralesional bleomycin, administered at one-month intervals, and was monitored for a minimum of six months post-treatment.Therapeutic efficacy was assessed based on changes in lesion color and area reduction. Outcomes were analyzed using ImagePro Plus (IPP) 6.0 software and SPSS Statistics software.

Results

Twenty-three lesions of 12 patients with unilateral or bilateral XP were included. The median age of patients was 28.5 years, with 75% being female.Hypercholesteremia was present in 58.3%. XP duration ranged from 1-5 years in 58.3% of cases. Most XP lesions were on the upper eyelids (65.2%). Improvement was observed in 56.5% of lesions, and 34.8% lesions were no longer visible. Adverse effects included temporary post-injection edema and swelling in 60% of patients and pigmentation at the injection site in two lesions. No serious complications or recurrence of XP were observed within 12 months post-treatment.

Conclusion

The visible improvement in xanthelasma lesions, minimal adverse effects, and absence of recurrence during the follow-up period highlight the potential of bleomycin as a promising non-surgical treatment option for XP.

Additional Authors

↑ Back to top